Next Evolution in 'Active' Myofunctional Treatment Launched at IDS 2019

In March 2019, Myofunctional Research Co. (MRC) unveiled its new Myotalea® treatment system to an audience of over 170,000 people at the 38th International Dental Show in Cologne, Germany. “Sleep disordered breathing was a hot topic at IDS 2019 and the newly released Myotalea® range of myofunctional treatment modalities is MRC’s latest innovation in the management of sleep-related breathing disorders,” said Mr Daniel Smith, MRC Operations Manager.